Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease

CompletedOBSERVATIONAL
Enrollment

63

Participants

Timeline

Start Date

June 24, 2019

Primary Completion Date

May 8, 2020

Study Completion Date

May 8, 2020

Conditions
Crohn´s Disease
Trial Locations (18)

1190

Sandoz Investigational Site, Vienna

5020

Sandoz Investigational Site, Salzburg

6020

Sandoz Investigational Site, Innsbruck

10825

Sandoz Investigational Site, Berlin

15405

Sandoz Investigational Site, Ferrol

24161

Sandoz Investigational Site, Altenholz

28040

Sandoz Investigational Site, Madrid

39319

Sandoz Investigational Site, Jerichow

44623

Sandoz Investigational Site, Herne

48159

Sandoz Investigational Site, Münster

55232

Sandoz Investigational Site, Alzey

58644

Sandoz Investigational Site, Iserlohn

66111

Sandoz Investigational Site, Saarbrücken

80331

Sandoz Investigational Site, Munich

85221

Sandoz Investigational Site, Dachau

97300

Sandoz Investigational Site, Piotrkow Trybunalski

87-800

Sandoz Investigational Site, Włocławek

701 85

Sandoz Investigational Site, Örebro

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sandoz

INDUSTRY

NCT03890445 - Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease | Biotech Hunter | Biotech Hunter